Cross-reactive epitopes on β2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome

Annals of the New York Academy of Sciences

Volumn 1108, Issue , 2007, Pages 481-488

  Krause, I ^a,b   Blank, M ^a,b   Cervera, R ^c   Font, J ^c   Matthias, T ^d   Pfeiffer, S ^d   Wies, I ^d   Fraser, A ^a   Shoenfeld, Y ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c HOSPITAL CLÍNIC   (Spain)

^d Research for Human Health   (Germany)

Author keywords

Autoimmunity; Crohn's disease; Mannan; 2 glycoprotein I

Indexed keywords

ANTIBODY; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; EPITOPE; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; CONTROLLED STUDY; CROSS REACTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SACCHAROMYCES CEREVISIAE;

SACCHAROMYCES CEREVISIAE;

EID: 34948873645     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1422.051     Document Type: Conference Paper

References (28)

1. SENDID, B. et al. 1996. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin. Diagn. Lab. Immunol. 3: 219-226.
2. QUINTON, J.F. et al. 1998. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42: 788-791.
3. KRAUSE, I. & G. MILO. 2004. Anti-Saccharomyces cerevisiae antibodies and autoimmune diseases. In Infection and Autoimmunity. Y. Shoenfeld & N.R. Rose, Eds.: 467-469. Elsevier Amsterdam, the Netherlands.
4. KRAUSE, I. et al. 2002. Anti-Saccharomyces cerevisiae antibodies - a novel serologic marker for Behcet's disease. Clin. Exp. Rheumatol. 20: S21-S24.
5. HOFFMAN, I.E. et al. 2003. Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann. Rheum. Dis. 62: 455-459.
6. REDDY, K.R. et al. 2001. Anti-Saccharomyces cerevisiae antibodies in autoimmune liver disease. Am. J. Gastroenterol. 96: 252-253.
7. MURATORI, P. et al. 2003. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin. Exp. Immunol. 132: 473-476.
8. DAMOISEAUX, J.G. et al. 2002. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease. J. Clin. Immunol. 22: 281-288.
9. LEVINE, J.S., D.W. BRANCH & J. RAUCH. 2002. The antiphospholipid syndrome. N. Engl. J. Med. 346: 752-763.
10. SHOENFELD, Y. 2003. Systemic antiphospholipid syndrome. Lupus 12: 497-498.
11. CERVERA, R. et al. 2002. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 46: 1019-1027.
12. CERVERA, R. et al. 1991. High prevalence of significant heart valve lesions in patients with the 'primary' antiphospholipid syndrome. Lupus 1: 43-47.
13. HOJNIK, M. et al. 1996. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93: 1579-1587.
14. LIBMAN, E. & B. SACKS. 1924. A hitherto undescribed form of valvular and mural endocarditis. Arch. Intern. Med. 33: 701-737.
15. HUGHES, G.R., N.N. HARRIS & A.E. GHARAVI. 1986. The anticardiolipin syndrome. J. Rheumatol. 13: 486-489.
16. SCHWARZENBACHER, R. et al. 1999. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. Embo J. 18: 6228-6239.
17. BOUMA, B. et al. 1999. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 18: 5166-5174.
18. BLANK, M. et al. 2002. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J. Clin. Invest. 109: 797-804.
19. GHARAVI, A.E. et al. 2002. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum. 46: 545-552.
20. WILSON, W.A. et al. 1999. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42: 1309-1311.
21. RUEMMELE, F.M. et al. 1998. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 115: 822-829.
22. PEETERS, M. et al. 2001. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am. J. Gastroenterol. 96: 730-734.
23. POLZ, E. & G.M. KOSTNER. 1979. The binding of beta 2-glycoprotein-I to human serum lipoproteins: distribution among density fractions. FEBS Lett. 102: 183-186.
24. LOZIER, J., N. TAKAHASHI & F.W. PUTNAM. 1984. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc. Natl. Acad. Sci. USA 81: 3640-3644.
25. KAMBOH, M.I., R.E. FERRELL & B. SEPEHRNIA. 1988. Genetic studies of human apolipoproteins. IV. Structural heterogeneity of apolipoprotein H (beta 2-glycoprotein I). Am. J. Hum. Genet. 42: 452-457.
26. KOUTROUBAKIS, I.E. et al. 1998. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig. Dis. Sci. 43: 2507-2512.
27. AICHBICHLER, B.W. et al. 1999. Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig. Dis. Sci. 44: 852-856.
28. ISRAELI, E. et al. 2005. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54: 1232-1236.